Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.980
-0.020 (-1.00%)
Nov 20, 2024, 4:00 PM EST - Market closed
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $133.04 million as of November 21, 2024. Its market cap has increased by 2,315.08% in one year.
Market Cap
133.04M
Enterprise Value
130.01M
1-Year Change
2,315.08%
Ranking
Category
Stock Price
$1.98
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $133.04M, an increase of 32.44%. That is a compound annual growth rate of 7.45%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Nov 19, 2024 | 134.39M | 1,613.80% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| PepGen | 134.62M |
| Acumen Pharmaceuticals | 134.58M |
| Puma Biotechnology | 134.50M |
| Zentek | 132.60M |
| Cabaletta Bio | 131.97M |
| Cardiff Oncology | 131.93M |
| Avalo Therapeutics | 129.32M |
| Innate Pharma | 128.52M |